Background
Phase III, randomized, open-label, global trial of polatuzumab vedotin (CD79b-directed antibody-drug conjugate) added to R-GemOx in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). After a 15-patient safety run-in, 255 patients with R/R DLBCL (NOS or transformed indolent lymphoma), ineligible for autologous stem-cell transplant and with ≥1 prior line, were randomized 1:1.
Results
Interventions and follow up: Arm A: Pola-R-GemOx — polatuzumab vedotin 1.8 mg/kg IV + rituximab 375 mg/m² + gemcitabine 1000 mg/m² + oxaliplatin 100 mg/m² every 21 days, up to 8 cycles (n=129).
Arm B: R-GemOx (same backbone without polatuzumab) every 21 days, up to 8 cycles (n=126).
Primary endpoint: Overall survival (OS).
mFollow up: 24.6 months.
Results: OS: 19.5 vs 12.5 mo; HR 0.60 (95% CI 0.43–0.83); P=.0017.
PFS: 7.4 vs 2.7 mo (significantly improved).
ORR / CR: Both improved with Pola-R-GemOx; exact rates NR in primary report.
Arm B: R-GemOx (same backbone without polatuzumab) every 21 days, up to 8 cycles (n=126).
Primary endpoint: Overall survival (OS).
mFollow up: 24.6 months.
Results: OS: 19.5 vs 12.5 mo; HR 0.60 (95% CI 0.43–0.83); P=.0017.
PFS: 7.4 vs 2.7 mo (significantly improved).
ORR / CR: Both improved with Pola-R-GemOx; exact rates NR in primary report.
Adverse events
Neurologic: peripheral neuropathy 50.7% (improved/resolved in most).
Hematologic: febrile neutropenia 2.3% vs 2.4% (grade ≥3).
Overall: toxicity consistent with the individual components; grade ≥3 composite NR.
Hematologic: febrile neutropenia 2.3% vs 2.4% (grade ≥3).
Overall: toxicity consistent with the individual components; grade ≥3 composite NR.
Conclusions
Adding polatuzumab vedotin to R-GemOx significantly prolonged OS (40% lower risk of death) in transplant-ineligible R/R DLBCL. Pola-R-GemOx provides an accessible chemoimmunotherapy option for patients not suited to transplant or cellular therapy.
Key Limitations
Open-label design; absolute OS gain modest (≈7 months); R-GemOx is a comparatively weak comparator in an era of CAR-T and bispecific antibodies; results apply specifically to transplant-ineligible patients; ORR/CR and PFS hazard-ratio detail limited in the primary readout.
Clinical Context
Offers a chemotherapy-based regimen for transplant-ineligible second-line and later R/R DLBCL, a space now populated by CAR-T (axi-cel, liso-cel), bispecifics (epcoritamab, glofitamab), and tafasitamab- or polatuzumab-based combinations. Polatuzumab is already approved in first-line (POLARIX, pola-R-CHP) and with bendamustine–rituximab; NCCN lists polatuzumab-containing regimens for relapsed disease. Not a new regulatory approval.